| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0166-6851(87)90189-7 |
| P698 | PubMed publication ID | 2437453 |
| P2093 | author name string | Heidrich HG | |
| McBride JS | |||
| P433 | issue | 1 | |
| P921 | main subject | Plasmodium falciparum | Q311383 |
| merozoite | Q2296434 | ||
| P304 | page(s) | 71-84 | |
| P577 | publication date | 1987-02-01 | |
| P1433 | published in | Molecular and Biochemical Parasitology | Q15752756 |
| P1476 | title | Fragments of the polymorphic Mr 185,000 glycoprotein from the surface of isolated Plasmodium falciparum merozoites form an antigenic complex | |
| P478 | volume | 23 |
| Q68146774 | A 46,000 dalton Plasmodium falciparum merozoite surface glycoprotein not related to the 185,000-195,000 dalton schizont precursor molecule: isolation and characterization |
| Q41942680 | A Plasmodium vivax vaccine candidate displays limited allele polymorphism, which does not restrict recognition by antibodies. |
| Q33195225 | A co-ligand complex anchors Plasmodium falciparum merozoites to the erythrocyte invasion receptor band 3. |
| Q54216698 | A comprehensive model for assessment of liver stage therapies targeting Plasmodium vivax and Plasmodium falciparum. |
| Q40872637 | A conserved region of the MSP-1 surface protein of Plasmodium falciparum contains a recognition sequence for erythrocyte spectrin |
| Q39387268 | A longitudinal study of naturally acquired cellular and humoral immune responses to a merozoite surface protein (MSP1) of Plasmodium falciparum in an area of seasonal malaria transmission. |
| Q34071439 | A malaria vaccine based on the polymorphic block 2 region of MSP-1 that elicits a broad serotype-spanning immune response |
| Q30043444 | A multifunctional serine protease primes the malaria parasite for red blood cell invasion |
| Q34420625 | A multigene family that interacts with the amino terminus of plasmodium MSP-1 identified using the yeast two-hybrid system |
| Q27230077 | A novel Plasmodium falciparum rhoptry associated adhesin mediates erythrocyte invasion through the sialic-acid dependent pathway |
| Q37529646 | A novel malaria vaccine candidate antigen expressed in Tetrahymena thermophila. |
| Q38952180 | A principal target of human immunity to malaria identified by molecular population genetic and immunological analyses |
| Q33276054 | A recombinase system facilitates cloning of expression cassettes in the ciliate Tetrahymena thermophila |
| Q35557563 | A second merozoite surface protein (MSP-4) of Plasmodium falciparum that contains an epidermal growth factor-like domain |
| Q36352078 | A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies. |
| Q45760438 | Addition of the MSA1 signal and anchor sequences to the malaria merozoite surface antigen 1 C-terminal region enhances immunogenicity when expressed by recombinant vaccinia virus |
| Q39598711 | An additional primary proteolytic processing site merozoite surface protein-1 of Plasmodium berghei |
| Q34334187 | Analysis of antibodies directed against merozoite surface protein 1 of the human malaria parasite Plasmodium falciparum |
| Q73261388 | Analysis of recombinant merozoite surface protein-1 of Plasmodium falciparum expressed in mammalian cells |
| Q37364827 | Annotation and characterization of the Plasmodium vivax rhoptry neck protein 4 (PvRON4) |
| Q33761687 | Antibodies against multiple merozoite surface antigens of the human malaria parasite Plasmodium falciparum inhibit parasite maturation and red blood cell invasion |
| Q36380869 | Antibodies that inhibit malaria merozoite surface protein-1 processing and erythrocyte invasion are blocked by naturally acquired human antibodies |
| Q37582802 | Antibodies to the N-terminal block 2 of plasmodium falciparum merozoite surface protein 1 are associated with protection against clinical malaria |
| Q48006728 | Antibody and clinical responses in volunteers to immunization with malaria peptide-diptheria toxoid conjugates |
| Q37452080 | Antibody responses to a novel Plasmodium falciparum merozoite surface protein vaccine correlate with protection against experimental malaria infection in Aotus monkeys |
| Q38625368 | Antigenic Variation in Plasmodium falciparum |
| Q48036521 | Antigenicity of recombinant proteins derived from Plasmodium falciparum merozoite surface protein 1. |
| Q56451852 | Characterization of C-terminal merozoite surface protein-1 baculovirus recombinant proteins from Plasmodium vivax and Plasmodium cynomolgi as recognized by the natural anti-parasite immune response |
| Q37522507 | Characterization of a novel inhibitory human monoclonal antibody directed against Plasmodium falciparum Apical Membrane Antigen 1. |
| Q33680865 | Competition between Plasmodium falciparum strains in clinical infections during in vitro culture adaptation |
| Q28254075 | Continuous culture of Plasmodium falciparum: its impact on malaria research |
| Q42571297 | Cryptosporidium parvum glycoprotein gp40 localizes to the sporozoite surface by association with gp15. |
| Q27641117 | Crystal structure of a Fab complex formed with PfMSP1-19, the C-terminal fragment of merozoite surface protein 1 from Plasmodium falciparum: a malaria vaccine candidate |
| Q44438134 | Development and pre-clinical analysis of a Plasmodium falciparum Merozoite Surface Protein-1(42) malaria vaccine |
| Q39518517 | Differential patterns of human immunoglobulin G subclass responses to distinct regions of a single protein, the merozoite surface protein 1 of Plasmodium falciparum |
| Q37597218 | Diversity and population structure of Plasmodium falciparum in Thailand based on the spatial and temporal haplotype patterns of the C-terminal 19-kDa domain of merozoite surface protein-1 |
| Q36826984 | Diversity covering AMA1-MSP119 fusion proteins as malaria vaccines |
| Q42913357 | Enhanced protection against malaria by a chimeric merozoite surface protein vaccine |
| Q47999588 | Epitopes in the 19kDa fragment of the Plasmodium falciparum major merozoite surface protein-1 (PfMSP-1(19)) recognized by human antibodies |
| Q34513240 | Erythrocyte invasion receptors for Plasmodium falciparum: new and old. |
| Q41985489 | Evaluation of recombinant Plasmodium knowlesi merozoite surface protein-1(33) for detection of human malaria |
| Q36155945 | Evaluation of the immunogenicity and vaccine potential of recombinant Plasmodium falciparum merozoite surface protein 8. |
| Q35689215 | Expression of merozoite surface protein markers by Plasmodium falciparum-infected erythrocytes in peripheral blood and tissues of children with fatal malaria |
| Q34249359 | Fine specificity of anti-MSP119 antibodies and multiplicity of Plasmodium falciparum merozoite surface protein 1 types in individuals in Nigeria with sub-microscopic infection |
| Q36576319 | Fine specificity of serum antibodies to Plasmodium falciparum merozoite surface protein, PfMSP-1(19), predicts protection from malaria infection and high-density parasitemia |
| Q37911988 | Genetic diversity in Plasmodium falciparum |
| Q34739743 | Global identification of multiple substrates for Plasmodium falciparum SUB1, an essential malarial processing protease |
| Q30409373 | Histidine affinity tags affect MSP1(42) structural stability and immunodominance in mice |
| Q27230084 | Host cell invasion by malaria parasites |
| Q47845842 | Human antibodies to the 19kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro |
| Q40150215 | Human antibody response to the major merozoite surface antigen of Plasmodium falciparum is strain specific and short-lived |
| Q27230016 | Identification and characterization of a novel Plasmodium falciparum adhesin involved in erythrocyte invasion |
| Q34842236 | Immunity to asexual blood stage malaria and vaccine approaches |
| Q37425845 | Immunogenicity of bacterial-expressed recombinant Plasmodium knowlesi merozoite surface protein-142 (MSP-142). |
| Q37451160 | Inhibition of erythrocyte invasion and Plasmodium falciparum merozoite surface protein 1 processing by human immunoglobulin G1 (IgG1) and IgG3 antibodies. |
| Q43570770 | Inhibitory monoclonal antibodies recognise epitopes adjacent to a proteolytic cleavage site on the RAP-1 protein of Plasmodium falciparum |
| Q30714235 | Interaction between two domains of the P. yoelii MSP-1 protein detected using the yeast two-hybrid system |
| Q48034944 | Interactions between merozoite surface proteins 1, 6, and 7 of the malaria parasite Plasmodium falciparum |
| Q68191266 | Isolation and characterization of the 80,000 dalton Plasmodium falciparum merozoite surface antigen |
| Q39228943 | Longitudinal study of Plasmodium falciparum polymorphic antigens in a malaria-endemic population |
| Q48019372 | Lymphocyte response in vitro to Plasmodium falciparum merozoite antigens in donors from a holoendemic area |
| Q42151010 | MSP-1p42-specific antibodies affect growth and development of intra-erythrocytic parasites of Plasmodium falciparum |
| Q47862670 | MSP1(19) miniproteins can serve as targets for invasion inhibitory antibodies in Plasmodium falciparum provided they contain the correct domains for cell surface trafficking |
| Q39557743 | Malaria parasite invasion: interactions with the red cell membrane |
| Q36313955 | Malaria vaccine-related benefits of a single protein comprising Plasmodium falciparum apical membrane antigen 1 domains I and II fused to a modified form of the 19-kilodalton C-terminal fragment of merozoite surface protein 1 |
| Q35549892 | Members of the merozoite surface protein 7 family with similar expression patterns differ in ability to protect against Plasmodium yoelii malaria |
| Q27972789 | Multiple Plasmodium falciparum Merozoite Surface Protein 1 Complexes Mediate Merozoite Binding to Human Erythrocytes |
| Q48028223 | N-linked glycoproteins are related to schizogony of the intraerythrocytic stage in Plasmodium falciparum |
| Q33983377 | Native-state stability determines the extent of degradation relative to secretion of protein variants from Pichia pastoris. |
| Q34541366 | Naturally acquired human antibodies which recognize the first epidermal growth factor-like module in the Plasmodium falciparum merozoite surface protein 1 do not inhibit parasite growth in vitro |
| Q47889065 | New World monkey efficacy trials for malaria vaccine development: critical path or detour? |
| Q33759208 | Passive immunization with antibodies against three distinct epitopes on Plasmodium yoelii merozoite surface protein 1 suppresses parasitemia |
| Q33281394 | Phase 1 study of two merozoite surface protein 1 (MSP1(42)) vaccines for Plasmodium falciparum malaria |
| Q35805390 | Plasmodium falciparum 19-kilodalton merozoite surface protein 1 (MSP1)-specific antibodies that interfere with parasite growth in vitro can inhibit MSP1 processing, merozoite invasion, and intracellular parasite development |
| Q40706910 | Plasmodium falciparum: Rosettes do not protect merozoites from invasion-inhibitory antibodies |
| Q28550605 | Plasmodium vivax Tryptophan Rich Antigen PvTRAg36.6 Interacts with PvETRAMP and PvTRAg56.6 Interacts with PvMSP7 during Erythrocytic Stages of the Parasite |
| Q39244294 | Population genetics ofPlasmodium falciparumwithin a malaria hyperendemic area |
| Q41844553 | Prediction of merozoite surface protein 1 and apical membrane antigen 1 vaccine efficacies against Plasmodium chabaudi malaria based on prechallenge antibody responses |
| Q35464579 | Primary structure of the variable region of monoclonal antibody 2B10, capable of inducing anti-idiotypic antibodies that recognize the C-terminal region of MSA-1 of Plasmodium falciparum. |
| Q27972787 | Processing of Plasmodium falciparum Merozoite Surface Protein MSP1 Activates a Spectrin-Binding Function Enabling Parasite Egress from RBCs |
| Q33282524 | Production of high-affinity human monoclonal antibody fab fragments to the 19-kilodalton C-terminal merozoite surface protein 1 of Plasmodium falciparum |
| Q35875731 | Proteases in host cell invasion by the malaria parasite |
| Q33356029 | Protection induced by Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and correlates with antibody responses |
| Q42415030 | Protective immune responses elicited by immunization with a chimeric blood-stage malaria vaccine persist but are not boosted by Plasmodium yoelii challenge infection |
| Q28345224 | Protective immune responses to the 42-kilodalton (kDa) region of Plasmodium yoelii merozoite surface protein 1 are induced by the C-terminal 19-kDa region but not by the adjacent 33-kDa region |
| Q40701948 | Proteins on the surface of the malaria parasite and cell invasion |
| Q40501263 | Purification of Plasmodium falciparum merozoites for analysis of the processing of merozoite surface protein-1. |
| Q37172951 | Quantification of Plasmodium falciparum malaria from complex infections in the Peruvian Amazon using quantitative PCR of the merozoite surface protein 1, block 2 (PfMSP1-B2): in vitro dynamics reveal density-dependent interactions |
| Q34081745 | Quantifying the importance of MSP1-19 as a target of growth-inhibitory and protective antibodies against Plasmodium falciparum in humans |
| Q34369560 | Regulated maturation of malaria merozoite surface protein‐1 is essential for parasite growth |
| Q27321307 | Revealing the sequence and resulting cellular morphology of receptor-ligand interactions during Plasmodium falciparum invasion of erythrocytes |
| Q36890504 | Seroepidemiology of Plasmodium species infections in Zimbabwean population |
| Q35383761 | Serum antibodies from malaria-exposed people recognize conserved epitopes formed by the two epidermal growth factor motifs of MSP1(19), the carboxy-terminal fragment of the major merozoite surface protein of Plasmodium falciparum |
| Q40373716 | Specific T-cell recognition of the merozoite proteins rhoptry-associated protein 1 and erythrocyte-binding antigen 1 of plasmodium falciparum |
| Q27640198 | Structure of the C-terminal domains of merozoite surface protein-1 from Plasmodium knowlesi reveals a novel histidine binding site |
| Q28740432 | T cell epitope regions of the P. falciparum MSP1-33 critically influence immune responses and in vitro efficacy of MSP1-42 vaccines |
| Q27230100 | The 22 kDa component of the protein complex on the surface of Plasmodium falciparum merozoites is derived from a larger precursor, merozoite surface protein 7 |
| Q37483845 | The 3' portion of the gene for a Plasmodium yoelii merozoite surface antigen encodes the epitope recognized by a protective monoclonal antibody |
| Q37559892 | The carboxy-terminus of merozoite surface protein 1: structure, specific antibodies and immunity to malaria. |
| Q33558061 | The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites |
| Q39104551 | The complete sequence of Plasmodium berghei merozoite surface protein-1 and its inter- and intra-species variability |
| Q34131183 | The human immune response to Plasmodium falciparum includes both antibodies that inhibit merozoite surface protein 1 secondary processing and blocking antibodies |
| Q27974532 | The merozoite surface protein 1 complex is a platform for binding to human erythrocytes by Plasmodium falciparum |
| Q44737449 | The merozoite surface protein 1 complex of human malaria parasite Plasmodium falciparum: interactions and arrangements of subunits |
| Q47876644 | The merozoite surface protein 6 gene codes for a 36 kDa protein associated with the Plasmodium falciparum merozoite surface protein-1 complex |
| Q46938146 | Transcription of the gene for the merozoite surface antigen MSA2 of the human malaria parasite Plasmodium falciparum during the asexual cycle |
| Q38533026 | Tumour necrosis factor and interleukin-6 production induced by components associated with merozoite proteins of Plasmodium falciparum |
| Q34003578 | Vaccine efficacy of recombinant Plasmodium falciparum merozoite surface protein 1 in malaria-naive, -exposed, and/or -rechallenged Aotus vociferans monkeys |
Search more.